CN115068363A - 一种地龙多肽冻干粉及其在护肤品中的应用 - Google Patents
一种地龙多肽冻干粉及其在护肤品中的应用 Download PDFInfo
- Publication number
- CN115068363A CN115068363A CN202210921114.4A CN202210921114A CN115068363A CN 115068363 A CN115068363 A CN 115068363A CN 202210921114 A CN202210921114 A CN 202210921114A CN 115068363 A CN115068363 A CN 115068363A
- Authority
- CN
- China
- Prior art keywords
- percent
- dried powder
- freeze
- extract
- lumbrokinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 47
- 241000361919 Metaphire sieboldi Species 0.000 title claims abstract description 18
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 18
- 108010070324 lumbrokinase Proteins 0.000 claims abstract description 48
- 241001233061 earthworms Species 0.000 claims abstract description 29
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001099 ammonium carbonate Substances 0.000 claims abstract description 28
- 235000012501 ammonium carbonate Nutrition 0.000 claims abstract description 28
- 238000000605 extraction Methods 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 43
- 239000006071 cream Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000002002 slurry Substances 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 22
- 230000008439 repair process Effects 0.000 claims description 22
- 230000002087 whitening effect Effects 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 15
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 14
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008158 vegetable oil Substances 0.000 claims description 11
- 239000000287 crude extract Substances 0.000 claims description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 235000002673 Dioscorea communis Nutrition 0.000 claims description 9
- 241000544230 Dioscorea communis Species 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 208000035753 Periorbital contusion Diseases 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 8
- 244000182216 Mimusops elengi Species 0.000 claims description 8
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 8
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- 229960000541 cetyl alcohol Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000005562 fading Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- -1 polydimethylsiloxane Polymers 0.000 claims description 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 claims description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- 240000001548 Camellia japonica Species 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229940110456 cocoa butter Drugs 0.000 claims description 3
- 235000019868 cocoa butter Nutrition 0.000 claims description 3
- 235000012716 cod liver oil Nutrition 0.000 claims description 3
- 239000003026 cod liver oil Substances 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 235000018597 common camellia Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 125000004386 diacrylate group Chemical group 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 229940064064 purslane extract Drugs 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 235000013599 spices Nutrition 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 27
- 238000005119 centrifugation Methods 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 238000004090 dissolution Methods 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 8
- 239000008176 lyophilized powder Substances 0.000 description 7
- 241000243684 Lumbricus Species 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21106—Hepsin (3.4.21.106)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于护肤品加工技术领域,具体涉及一种地龙多肽冻干粉及其在护肤品中的应用,以鲜活的地龙为原材料,利用碳酸铵配合不断的离心、溶解等提取工艺,获得具有较高酶活性且性质更加稳定的蚓激酶冻干粉,工艺简单高效;并将冻干粉用于化妆品,充分发挥蚓激酶冻干粉的功效,起到修复皮肤以及为皮肤提供充足营养的功效。
Description
技术领域
本发明属于护肤品加工技术领域,具体涉及一种地龙多肽冻干粉及其在护肤品中的应用。
背景技术
现代药理研究表明,地龙具有清热定惊、平喘、通络、利尿、降压、解热镇痛抗炎、促进伤口愈合、促进血液循环、增强免疫等作用。地龙提取物中最主要的起作用成分为蚓激酶;蚓激酶(Lumbrokinase,LK)是蚯蚓体内发现的一组同时具有纤溶活性和激酶活性的丝氨酸蛋白酶,此酶能够刺激纤溶酶原转变成纤溶酶,从而起到催化纤维蛋白以及溶血栓的作用。
护肤品已成为大众生活的必需品,而随着生活水平的提高,人们对护肤品的要求也越来越高,尤其是在功能、效果、安全性等多方面,均有更高的要求。目前,地龙提取物作为一种性能优异的提取物产品,其应用领域仍以口服药为主,在护肤品中的应用很少;即便有相关应用的实例,其对蚓激酶的提取以及在护肤领域的应用研究也不够深入,未将蚓激酶的功效得以最大化的发挥和利用。
发明内容
针对现有技术中的问题,本发明提供一种地龙多肽冻干粉,解决了现有蚓激酶的提取难点,利用碳酸铵配合离心、溶解等提取工艺,获得具有较高酶活性且性质更加稳定的蚓激酶冻干粉,提取工艺简单高效。
为实现以上技术目的,本发明的技术方案是:
一种地龙多肽冻干粉,其提取方法包括
步骤1,将鲜活的地龙放入水中,并滴加植物油,静置2-3h,然后取出地龙,所述地龙与水的质量比为1:5-10,所述植物油的加入量是水的0.05-0.1%,静置的温度为20-25℃;该步骤利用植物油将地龙中的泥垢去除,达到清理除杂的效果;
步骤2,将地龙放入纯化水中,搅拌成浆状,并加入碳酸铵直至搅拌溶解,然后恒温搅拌1-2h,得到浆料;所述碳酸铵在浆料中的浓度为20-40g/L,搅拌速度为100-200r/min,所述恒温搅拌的速度为500-1000r/min,温度为75℃;该步骤利用搅拌的机械力将地龙完全碎化,形成浆料状,并均匀分布在水中,利用碳酸铵自身的受热发泡特性,改善纯化水酸碱性的同时,实现浆料假沸并均匀化分散,确保蚓激酶提取物能够充分提取,达到提高了提取效率;
步骤3,将浆料离心处理并收集上清液,得到沉淀物;
步骤4,将PEG加入至上清液中搅拌溶解,并调节pH至5-6,得到第一提取液,所述PEG的分子量为1000-40000,且PEG在上清液的质量占比为1-20%;
步骤5,将沉淀物放入乙醇水溶液中搅拌,并加入碳酸铵,然后恒温离心,收集上清液,即,第二提取液,所述沉淀物在乙醇水中的浓度为100-300g/L,乙醇水溶液的乙醇体积占比为50-60%,所述碳酸铵的加入量是沉淀物质量的20-40%,所述恒温离心的温度为10-20℃;该步骤利用乙醇水混合液进行二次提取,利用乙醇和水自身的提取特性,形成稳定的醇提物和水提物,然后利用碳酸铵的气泡爆破力增加对沉淀物的破坏,增加表面的裸露,从而打动深入提取;
步骤6,将第一提取物和第二提取物混合,并静置得到蚓激酶粗提物,然后加入甘露醇充分搅拌,经过滤除菌得到蚓激酶提取物,所述静置的温度为50-60℃;所述甘露醇的加入量是蚓激酶粗提物质量的1-10%;利用静置的方式将第二提取物的乙醇挥发去除,形成以水为主溶剂的粗提物;
步骤7,将蚓激酶提取物进行冷冻、干燥、碾压,获得蚓激酶冻干粉。
一种地龙多肽冻干粉在护肤品中的应用,用于制备修护霜;该修护霜中,蚓激酶冻干粉的用量为0.3%-2%。
进一步地,该修护霜为祛红血丝美白霜。
更进一步地,该祛红血丝美白霜包括:蚓激酶冻干粉0.5%-2%、马齿苋提取物1%-3%、羊胎盘提取物2%-10%;硬脂酸2%-5%、单甘酯5%-10%、十八醇3%-8%、鲸蜡醇2%-5%、尼泊金乙酯0.05%-0.2%;苯甲酸钠0.1%-0.3%、乳化剂0.2%-1%、氢化蛋黄卵磷脂0.2%-1%、鱼肝油0.2%-1%、香精0.05%-0.2%、甘油10%-20%、去离子水余量。
所制备的祛红血丝美白霜中,蚓激酶的活性为20-50IU/g;该祛红血丝美白霜,可祛除红血丝,为皮肤提供营养成分,修复损伤肌肤。
进一步地,该修护霜为祛黑眼圈眼霜。
更进一步地,该祛黑眼圈眼霜包括:蚓激酶冻干粉0.3%-1%、羊胚胎胶原蛋白1%-3%;自乳化单硬脂酸甘油酯1%-2%、十六十八醇1%-2%、角鲨烷3%-5%、山茶籽油1%-2%、布里奇果油0.1%-1%、氢化可可脂0.5%-2%、异十六烷3%-5%、聚二甲基硅氧烷1.5%-5%、辅酶Q10脂质体1%-3%;甘油4%-7%、1,3丁二醇3%-5%、透明质酸钠0.01%-0.1%、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物0.2%-0.5%、EDTA-2Na0.01%-0.1%、甜菜碱2%-3%、聚丙烯酰胺和聚乙二醇二丙烯酸酯的混合物0.1%-1%、苯氧乙醇0.1%-1%、去离子水余量。
所制备的祛黑眼圈眼霜中,蚓激酶的活性为18-22IU/g;该祛黑眼圈眼霜,可祛除黑眼圈,并为眼周皮肤提供充足的营养。
进一步地,该修护霜为淡斑美白修复霜。
更进一步地,该淡斑美白修复霜包括:蚓激酶冻干粉0.3%-1%、中药复方提取物1%-3%、枸杞提取物1%-3%、香料0.01%-0.2%;丙二醇二辛酸酯/二癸酯12%-18%、硬脂酸甘油酯3%-6%、十四酸十四酯0.5%-2%、硬脂醇1%-3%、十六醇1%-2%;羟乙基纤维素0.5%-2%、甘油2%-4%、丙二醇1%-3%、尼泊金甲酯0.1%-0.3%、异硬脂酰胺丙基PG-二甲基氯化铵10%-15%、去离子水余量。
更进一步地,中药复方提取物中的中药组分包括甘草、苦豆子、白芨、丹参。
所制备的淡斑美白修复霜,可起到促进皮肤血液循环、促进皮肤代谢、修复损伤肌肤的作用,有效淡斑和美白皮肤。
从以上描述可以看出,本发明具备以下优点:
1.本发明解决了现有蚓激酶的提取难点,利用碳酸铵配合离心、溶解等提取工艺,获得具有较高酶活性且性质更加稳定的蚓激酶冻干粉,提取工艺简单高效。
2.本发明将蚓激酶冻干粉作为原料用于化妆品的制备,可制备各类具有修复功能的护肤霜产品,通过限定蚓激酶冻干粉的活性和添加量,充分发挥蚓激酶冻干粉的功效,起到修复皮肤以及为皮肤提供充足营养的功效。
具体实施方式
结合实施例详细说明本发明,但不对本发明的权利要求做任何限定。
实施例1
一种地龙多肽冻干粉,其提取方法包括
步骤1,将鲜活的地龙放入水中,并滴加植物油,静置2h,然后取出地龙,所述地龙与水的质量比为1:5,所述植物油的加入量是水的0.05%,静置的温度为20℃;
步骤2,将地龙放入纯化水中,搅拌成浆状,并加入碳酸铵直至搅拌溶解,然后恒温搅拌1h,得到浆料;所述碳酸铵在浆料中的浓度为20g/L,搅拌速度为100r/min,所述恒温搅拌的速度为500r/min,温度为75℃;
步骤3,将浆料离心处理并收集上清液,得到沉淀物;
步骤4,将PEG加入至上清液中搅拌溶解,并调节pH至5,得到第一提取液,所述PEG的分子量为1000-40000,且PEG在上清液的质量占比为1%;
步骤5,将沉淀物放入乙醇水溶液中搅拌,并加入碳酸铵,然后恒温离心,收集上清液,即,第二提取液,所述沉淀物在乙醇水中的浓度为100g/L,乙醇水溶液的乙醇体积占比为50%,所述碳酸铵的加入量是沉淀物质量的20%,所述恒温离心的温度为10℃;
步骤6,将第一提取物和第二提取物混合,并静置得到蚓激酶粗提物,然后加入甘露醇充分搅拌,经过滤除菌得到蚓激酶提取物,所述静置的温度为50℃;所述甘露醇的加入量是蚓激酶粗提物质量的1%;
步骤7,将蚓激酶提取物进行冷冻、干燥、碾压,获得蚓激酶冻干粉。
采用上述的提取方法所提取的蚓激酶冻干粉,以尿激酶为标准品,测定其活性为30000IU/g。
实施例2
一种地龙多肽冻干粉,其提取方法包括
步骤1,将鲜活的地龙放入水中,并滴加植物油,静置2-3h,然后取出地龙,所述地龙与水的质量比为1:10,所述植物油的加入量是水的0.1%,静置的温度为25℃;
步骤2,将地龙放入纯化水中,搅拌成浆状,并加入碳酸铵直至搅拌溶解,然后恒温搅拌2h,得到浆料;所述碳酸铵在浆料中的浓度为40g/L,搅拌速度为200r/min,所述恒温搅拌的速度为1000r/min,温度为75℃;
步骤3,将浆料离心处理并收集上清液,得到沉淀物;
步骤4,将PEG加入至上清液中搅拌溶解,并调节pH至6,得到第一提取液,所述PEG的分子量为1000-40000,且PEG在上清液的质量占比为20%;
步骤5,将沉淀物放入乙醇水溶液中搅拌,并加入碳酸铵,然后恒温离心,收集上清液,即,第二提取液,所述沉淀物在乙醇水中的浓度为300g/L,乙醇水溶液的乙醇体积占比为60%,所述碳酸铵的加入量是沉淀物质量的40%,所述恒温离心的温度为20℃;
步骤6,将第一提取物和第二提取物混合,并静置得到蚓激酶粗提物,然后加入甘露醇充分搅拌,经过滤除菌得到蚓激酶提取物,所述静置的温度为60℃;所述甘露醇的加入量是蚓激酶粗提物质量的10%;
步骤7,将蚓激酶提取物进行冷冻、干燥、碾压,获得蚓激酶冻干粉。
采用上述的提取方法所提取的蚓激酶冻干粉,以尿激酶为标准品,测定其活性为40000IU/g。
实施例3
一种地龙多肽冻干粉,其提取方法包括
步骤1,将鲜活的地龙放入水中,并滴加植物油,静置3h,然后取出地龙,所述地龙与水的质量比为1:8,所述植物油的加入量是水的0.08%,静置的温度为23℃;该步骤利用植物油将地龙中的泥垢去除,达到清理除杂的效果;
步骤2,将地龙放入纯化水中,搅拌成浆状,并加入碳酸铵直至搅拌溶解,然后恒温搅拌2h,得到浆料;所述碳酸铵在浆料中的浓度为30g/L,搅拌速度为200r/min,所述恒温搅拌的速度为800r/min,温度为75℃;
步骤3,将浆料离心处理并收集上清液,得到沉淀物;
步骤4,将PEG加入至上清液中搅拌溶解,并调节pH至5,得到第一提取液,所述PEG的分子量为1000-40000,且PEG在上清液的质量占比为10%;
步骤5,将沉淀物放入乙醇水溶液中搅拌,并加入碳酸铵,然后恒温离心,收集上清液,即,第二提取液,所述沉淀物在乙醇水中的浓度为200g/L,乙醇水溶液的乙醇体积占比为50%,所述碳酸铵的加入量是沉淀物质量的30%,所述恒温离心的温度为15℃;
步骤6,将第一提取物和第二提取物混合,并静置得到蚓激酶粗提物,然后加入甘露醇充分搅拌,经过滤除菌得到蚓激酶提取物,所述静置的温度为55℃;所述甘露醇的加入量是蚓激酶粗提物质量的5%;
步骤7,将蚓激酶提取物进行冷冻、干燥、碾压,获得蚓激酶冻干粉。
采用上述的提取方法所提取的蚓激酶冻干粉,以尿激酶为标准品,测定其活性为50000IU/g。
实施例4
一种祛红血丝美白霜,包括如下原料:
A相:来自实施例3的蚓激酶冻干粉1%、马齿苋提取物2%、羊胎盘提取物8%;
B相:硬脂酸3%、单甘酯7%、十八醇5%、鲸蜡醇3%、尼泊金乙酯0.1%;
C相:苯甲酸钠0.15%、乳化剂0.5%、氢化蛋黄卵磷脂0.5%、鱼肝油0.5%、香精0.1%、甘油15%、去离子水余量。
祛红血丝美白霜的制备方法为:将B相、C相的各个原料分别在85-90℃下加热,再转移至乳化罐中并进行搅拌,当温度降至35-45℃时,加入A相并搅拌均匀,再进行灌装,获得祛红血丝美白霜。
经过实验验证,蚓激酶冻干粉的添加量不能超过2%,若添加的量过高,会引起皮肤干燥,若添加量过过少,则无法显效,因而,祛红血丝美白霜的添加量在0.5-2%之间最为合适。
通过蚓激酶活性测定方法测定祛红血丝美白霜中蚓激酶的活性并验证,其活性保持在20-50IU/g为最佳,可使其充分发挥促进血液循环、修复损伤肌肤的作用。
另外,马齿苋提取物具有消肿、消炎、抗过敏的作用;羊胎盘提取物可为肌肤补充足够的营养,促进肌肤修复。
实施例5
一种祛黑眼圈眼霜,其质量配比包括:
A相:来自实施例3的蚓激酶冻干粉0.6%、羊胚胎胶原蛋白2%;
B相:自乳化单硬脂酸甘油酯(产品牌号为ARLACEL 170)1.5%、十六十八醇1.5%、角鲨烷4%、山茶籽油1.5%、布里奇果油0.5%、氢化可可脂1%、异十六烷4%、聚二甲基硅氧烷2%、辅酶Q10脂质体1.6%;
C相:甘油5%、1,3丁二醇4%、透明质酸钠0.05%、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物(产品牌号为EMT-10)0.35%、EDTA-2Na 0.05%、甜菜碱2.5%、聚丙烯酰胺和聚乙二醇二丙烯酸酯的混合物(产品牌号为SEPLGEL 305)0.6%、苯氧乙醇0.5%、去离子水余量。
祛黑眼圈眼霜的制备方法为:将B相的所有成分进行混合并搅拌加热至80℃,再将C相的所有成分进行混合并加热至85℃,最后将C相倒入B相中,均质2-3分钟,待搅拌温度降至45℃,依次加入A相各组分,搅拌均匀后灌装,获得祛黑眼圈眼霜。
经实验验证,蚓激酶冻干粉具有祛黑眼圈的作用,且其在眼霜中的添加量不宜超过1%;通过对祛黑眼圈眼霜的蚓激酶活性的测定可知,其酶活在20IU/g时,以及在低于1%的用量下,祛黑眼圈的效果最佳。
另外,羊胚胎胶原蛋白是由羊胚胎经过酶解纯化后获得的胶原蛋白,具有祛皱以及为皮肤补充营养的作用。
实施例6
一种淡斑美白修复霜,包括如下原料:
A相:蚓激酶冻干粉0.7%、中药复方提取物2%、枸杞提取物2%、香料0.1%;
B相:丙二醇二辛酸酯/二癸酯15%、硬脂酸甘油酯4.5%、十四酸十四酯1%、硬脂醇2%、十六醇1.5%;
C相:羟乙基纤维素1%、甘油3%、丙二醇2%、尼泊金甲酯0.2%、异硬脂酰胺丙基PG-二甲基氯化铵12%、去离子水余量。
其中,中药复方提取物中的中药组分包括甘草、苦豆子、白芨、丹参。
淡斑美白修复霜的制备方法为:在容器中依次加入水和C相的羟乙基纤维素并搅拌加热至78℃,待完全溶解后再加入C相的其余原料;在另一容器中加入B相的各个原料并加热到80℃,再进行搅拌和均质处理,并在搅拌和保温的状态下,将B相缓慢加入到C相中并持续搅拌,再冷却至40℃后添加A相并冷却至室温,获得淡斑美白修复霜。
经实验验证,在淡斑美白修复霜中,蚓激酶冻干粉起到协同作用,其添加量不易过大,最高不超过1%,使其可以更好的起到促进皮肤血液循环、促进皮肤代谢、修复损伤肌肤等作用;另外,枸杞提取物主要是利用宁夏枸杞提取的枸杞多糖、枸杞黄酮及枸杞发酵物的混合物,进一步起到淡斑美白修复的作用。
可以理解的是,以上关于本发明的具体描述,仅用于说明本发明而并非受限于本发明实施例所描述的技术方案。本领域的普通技术人员应当理解,仍然可以对本发明进行修改或等同替换,以达到相同的技术效果;只要满足使用需要,都在本发明的保护范围之内。
Claims (9)
1.一种地龙多肽冻干粉,其特征在于:其提取方法包括:
步骤1,将鲜活的地龙放入水中,并滴加植物油,静置2-3h,然后取出地龙;
步骤2,将地龙放入纯化水中,搅拌成浆状,并加入碳酸铵直至搅拌溶解,然后恒温搅拌1-2h,得到浆料;
步骤3,将浆料离心处理并收集上清液,得到沉淀物;
步骤4,将PEG加入至上清液中搅拌溶解,并调节pH至5-6,得到第一提取液,
步骤5,将沉淀物放入乙醇水溶液中搅拌,并加入碳酸铵,然后恒温离心,收集上清液,即,第二提取液;
步骤6,将第一提取物和第二提取物混合,并静置得到蚓激酶粗提物,然后加入甘露醇充分搅拌,经过滤除菌得到蚓激酶提取物;
步骤7,将蚓激酶提取物进行冷冻、干燥、碾压,获得蚓激酶冻干粉。
2.如权利要求1所述的基于蚓激酶提取物的冻干粉在护肤品中的应用,其特征在于:所述冻干粉用于制备修护霜;该修护霜中,蚓激酶冻干粉的用量为0.3%-2%。
3.根据权利要求2所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该修护霜为祛红血丝美白霜。
4.根据权利要求3所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该祛红血丝美白霜包括:蚓激酶冻干粉0.5%-2%、马齿苋提取物1%-3%、羊胎盘提取物2%-10%;硬脂酸2%-5%、单甘酯5%-10%、十八醇3%-8%、鲸蜡醇2%-5%、尼泊金乙酯0.05%-0.2%;苯甲酸钠0.1%-0.3%、乳化剂0.2%-1%、氢化蛋黄卵磷脂0.2%-1%、鱼肝油0.2%-1%、香精0.05%-0.2%、甘油10%-20%、去离子水余量。
5.根据权利要求2所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该修护霜为祛黑眼圈眼霜。
6.根据权利要求5所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该祛黑眼圈眼霜包括:蚓激酶冻干粉0.3%-1%、羊胚胎胶原蛋白1%-3%;自乳化单硬脂酸甘油酯1%-2%、十六十八醇1%-2%、角鲨烷3%-5%、山茶籽油1%-2%、布里奇果油0.1%-1%、氢化可可脂0.5%-2%、异十六烷3%-5%、聚二甲基硅氧烷1.5%-5%、辅酶Q10脂质体1%-3%;甘油4%-7%、1,3丁二醇3%-5%、透明质酸钠0.01%-0.1%、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物0.2%-0.5%、EDTA-2Na 0.01%-0.1%、甜菜碱2%-3%、聚丙烯酰胺和聚乙二醇二丙烯酸酯的混合物0.1%-1%、苯氧乙醇0.1%-1%、去离子水余量。
7.根据权利要求2所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该修护霜为淡斑美白修复霜。
8.根据权利要求7所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:该淡斑美白修复霜包括:蚓激酶冻干粉0.3%-1%、中药复方提取物1%-3%、枸杞提取物1%-3%、香料0.01%-0.2%;丙二醇二辛酸酯/二癸酯12%-18%、硬脂酸甘油酯3%-6%、十四酸十四酯0.5%-2%、硬脂醇1%-3%、十六醇1%-2%;羟乙基纤维素0.5%-2%、甘油2%-4%、丙二醇1%-3%、尼泊金甲酯0.1%-0.3%、异硬脂酰胺丙基PG-二甲基氯化铵10%-15%、去离子水余量。
9.根据权利要求8所述的地龙多肽冻干粉在护肤品中的应用,其特征在于:中药复方提取物中的中药组分包括甘草、苦豆子、白芨、丹参。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210921114.4A CN115068363A (zh) | 2022-08-02 | 2022-08-02 | 一种地龙多肽冻干粉及其在护肤品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210921114.4A CN115068363A (zh) | 2022-08-02 | 2022-08-02 | 一种地龙多肽冻干粉及其在护肤品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115068363A true CN115068363A (zh) | 2022-09-20 |
Family
ID=83241983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210921114.4A Pending CN115068363A (zh) | 2022-08-02 | 2022-08-02 | 一种地龙多肽冻干粉及其在护肤品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115068363A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1414095A (zh) * | 2002-08-30 | 2003-04-30 | 宁夏金丰源实业有限责任公司 | 高活性蚓激酶干粉的制备方法 |
CN102925421A (zh) * | 2012-11-27 | 2013-02-13 | 天津蚓福生物科技开发有限公司 | 一种蚓激酶的制备方法 |
CN105907738A (zh) * | 2016-07-06 | 2016-08-31 | 奥为(天津)环保科技有限公司 | 一种蚯蚓中蚓激酶高效提取的方法 |
CN106668131A (zh) * | 2016-11-01 | 2017-05-17 | 南京恒生制药有限公司 | 一种地龙组合物及其制备方法 |
CN107853635A (zh) * | 2017-11-10 | 2018-03-30 | 德兴市宋氏葛业有限公司 | 一种速溶改性葛粉的制备方法 |
CN109771462A (zh) * | 2017-11-11 | 2019-05-21 | 云南养尊堂生物科技有限公司 | 一种三七超细粉及其制备方法 |
CN110540550A (zh) * | 2019-07-31 | 2019-12-06 | 倪成 | 蚓激酶与粗制蚯蚓卵磷脂的联合制备工艺 |
CN110897982A (zh) * | 2019-10-26 | 2020-03-24 | 银川凤仪堂生物工程有限公司 | 一种蚓激酶冻干粉及其在护肤品中的应用 |
-
2022
- 2022-08-02 CN CN202210921114.4A patent/CN115068363A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1414095A (zh) * | 2002-08-30 | 2003-04-30 | 宁夏金丰源实业有限责任公司 | 高活性蚓激酶干粉的制备方法 |
CN102925421A (zh) * | 2012-11-27 | 2013-02-13 | 天津蚓福生物科技开发有限公司 | 一种蚓激酶的制备方法 |
CN105907738A (zh) * | 2016-07-06 | 2016-08-31 | 奥为(天津)环保科技有限公司 | 一种蚯蚓中蚓激酶高效提取的方法 |
CN106668131A (zh) * | 2016-11-01 | 2017-05-17 | 南京恒生制药有限公司 | 一种地龙组合物及其制备方法 |
CN107853635A (zh) * | 2017-11-10 | 2018-03-30 | 德兴市宋氏葛业有限公司 | 一种速溶改性葛粉的制备方法 |
CN109771462A (zh) * | 2017-11-11 | 2019-05-21 | 云南养尊堂生物科技有限公司 | 一种三七超细粉及其制备方法 |
CN110540550A (zh) * | 2019-07-31 | 2019-12-06 | 倪成 | 蚓激酶与粗制蚯蚓卵磷脂的联合制备工艺 |
CN110897982A (zh) * | 2019-10-26 | 2020-03-24 | 银川凤仪堂生物工程有限公司 | 一种蚓激酶冻干粉及其在护肤品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102293292B (zh) | 滋阴养血的保健茶及其加工方法 | |
CN113679765A (zh) | 白鲜皮提取物及其应用 | |
CN105902465A (zh) | 一种温和祛黄抗敏精华液 | |
CN102971415B (zh) | 血小板源性生长因子-bb产生增强剂、以及包含该增强剂的间充质系干细胞产生促进剂、干细胞稳定剂和真皮再生剂 | |
CN111617008A (zh) | 一种敏感肌修复组合物及其在化妆品中的应用 | |
CN105213256A (zh) | 一种舒敏祛红柔肤水及其制备方法 | |
CN115068363A (zh) | 一种地龙多肽冻干粉及其在护肤品中的应用 | |
CN110538123A (zh) | 一种美白祛斑的中药复方提取液的制备工艺及其应用 | |
CN107047864A (zh) | 慢性咽炎调理保健茶及其制备方法 | |
CN114010554B (zh) | 一种包裹中药提取物的缓释微囊及其制备方法和应用 | |
CN110897982A (zh) | 一种蚓激酶冻干粉及其在护肤品中的应用 | |
CN108420770A (zh) | 一种天然润泽面霜及其制备方法 | |
CN103181431B (zh) | 一种养肝保健茶及其制备方法 | |
JPH1075750A (ja) | にんにく系健康飲料 | |
CN114053164A (zh) | 一种具有抗炎祛痘促进皮肤再生修复功能的精华液及其制备方法 | |
CN102772644A (zh) | 具有消肿修复功效的中药组合物、制剂及其制备方法 | |
CN105997780A (zh) | 一种减少细纹提拉紧致面部化妆品 | |
CN105943443A (zh) | 一种含有金钗石斛的用于化妆品的美白中药组合物 | |
CN112716990A (zh) | 一种葵花盘提取物、含有葵花盘提取物的药物及制备方法和应用 | |
CN105902468A (zh) | 一种美白抗衰老的面霜 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN105055908A (zh) | 一种祛斑美白胶囊及其制备方法 | |
CN109248180A (zh) | 南洋山苏水萃物的用途 | |
CN113100442B (zh) | 一种蜂王浆龟鳖肽嚼含片及其制备工艺 | |
CN109077954A (zh) | 虫草面膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |